Drugs / pAKK\_LWHK0003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07488975 | Jan 2025 → Dec 2026 expected | metabolic dysfunction-associated steatotic liver disease | Leeuwenhoek Laboratories Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pAKK\_LWHK0003 | “Our previous research investigated a pasteurized Akkermansia muciniphila strain, NTUH\_Amuc03 (pAKK\_LWHK0003), which attenuated fatty liver progression in preclinical models.” NCT07488975 ↗ |
| Known as | NTUH\_Amuc03 | “Our previous research investigated a pasteurized Akkermansia muciniphila strain, NTUH\_Amuc03 (pAKK\_LWHK0003), which attenuated fatty liver progression in preclinical models.” NCT07488975 ↗ |